Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer Clinical Trial

Official title:
To Evaluate Real-World Effectiveness of Osimertinib for Patients With Advanced or Metastatic Epidermal Growth Factor Receptor 20exon Insertion Mutation (20ins) Non-Small Cell Lung Cancer (NSCLC)

Status Not yet recruiting

Clinical Trial Summary

This study is a retrospective real-world study to evaluate the efficacy of Osimertinib for patients with advanced or metastatic EGFR 20exon insertion mutation (20ins) Non-Small Cell Lung Cancer.

Clinical Trial Description

This is a multicenter, retrospective observational real-world study, which evaluates the efficacy of Osimertinib, between 2017 and 2022, in patients with advanced or metastatic EGFR 20exon insertion mutation (20ins) Non-Small Cell Lung Cancer. This study serves as the external control for a single arm phase II trial on JMT101 combined with Osimertinib in patients with Non-Small Cell Lung Cancer. The primary outcome measure is objective response rate (ORR). ;

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Lung Neoplasms

Clinical Trial Details

NCT number	NCT05513664
Study type	Observational
Source	Shanghai JMT-Bio Inc.
Contact	Lei Li
Phone	13711344347
Email	lclilei@mail.ecspc.com
Status	Not yet recruiting
Phase
Start date	September 2022
Completion date	August 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05048797` - A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations	Phase 3
Not yet recruiting	`NCT05132777` - Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer	Phase 2
Recruiting	`NCT04606446` - Study of PF-07248144 in Advanced or Metastatic Solid Tumors	Phase 1
Recruiting	`NCT05673590` - Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Phase 3
Recruiting	`NCT04686305` - Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC	Phase 1
Recruiting	`NCT04448379` - Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer	Phase 1
Recruiting	`NCT05863325` - A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)	Phase 2
Recruiting	`NCT04996121` - A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors	Phase 1/Phase 2